Skip to main content

Year: 2024

Microchip Adds MTCH2120 to its Portfolio of Turnkey Capacitive Touch Controllers

The touch controller is designed to integrate with a comprehensive ecosystem of tools to streamline development and speed time to market CHANDLER, Ariz., Dec. 18, 2024 (GLOBE NEWSWIRE) — Turnkey touch controllers are a fast and easy way to upgrade from mechanical buttons to modern touch buttons or displays. With the launch of its 12-button MTCH2120 touch controller, Microchip Technology (Nasdaq: MCHP) is providing designers with a straightforward pathway for implementing touch button capabilities on user interfaces. The low-power, water-tolerant turnkey touch device is integrated with Microchip’s unified ecosystem, allowing for an easier design process and facilitating transitions between other turnkey solutions and MCU-based touch implementations. The MTCH2120 is the first of what will be a family of I2C-based touch controllers...

Continue reading

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,602 shares of the Company’s common stock with an exercise price of $20.12, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The option vests as to 25% on December 12, 2025, and then in three equal annual installments...

Continue reading

Unit holder meeting in Storebrand Indeks – Nye Markeder on 13 January 2025

                                                                                                          Lysaker, 18 December 2024 Storebrand Asset Management AS hereby announces a unitholder meeting in Storebrand Indeks – Nye Markeder to be held on 13 January 2025. Background and Purpose Storebrand Asset Management proposes amendments to the Articles of Association for the Storebrand Indeks-Nye Markeder fund. The proposed changes will allow the fund to invest in companies with a weighting exceeding 10% of the benchmark index, ensuring that the fund can continue to reflect the characteristics of its benchmark index. This adjustment has become necessary as one company within the fund’s benchmark index, the MSCI Emerging Markets Index, represented 10% of the index as of October 30, 2024. The proposed amendment will align the...

Continue reading

FactSet Appoints Barak Eilam to Board of Directors

NORWALK, Conn., Dec. 18, 2024 (GLOBE NEWSWIRE) — FactSet (NYSE: FDS | NASDAQ: FDS), a global financial digital platform and enterprise solutions provider, today announced the appointment of Barak Eilam to its Board of Directors. He will also serve on FactSet’s Compensation and Talent Committee. Eilam brings nearly three decades of experience scaling enterprise software companies into global market leaders. He is serving as Chief Executive Officer (CEO) of NICE, a leading enterprise software company specializing in analytics and AI solutions, through the end of calendar year 2024. As CEO from 2014 to 2024, Eilam led the company through remarkable growth, tripling its revenue to nearly $3 billion, growing cloud revenue from almost zero to $2 billion, and more than quadrupling earnings per share. He began his career as an engineer...

Continue reading

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) — Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT (2:15 p.m. ET). A live webcast will be available on the Presentations portion of Entrada’s Investor Relations website at https://ir.entradatx.com. The webcast will be archived and available for replay for 30 days after the event. About Entrada TherapeuticsEntrada Therapeutics is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing...

Continue reading

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Oruka’s addition will become effective prior to market open on Monday, December 23rd, 2024. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average...

Continue reading

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced that the European Commission has adopted a positive decision for the designation of mitapivat, an oral, small molecule PK activator, as an orphan medicinal product (OMP) for the treatment of sickle cell disease. Earlier, in November 2020, the U.S. Food and Drug Administration (FDA) also granted orphan drug designation to mitapivat for sickle cell disease. “Alongside the FDA’s orphan drug designation in the U.S., the European Commission’s orphan medicinal product designation for mitapivat underscores the urgent need for novel therapies for sickle cell disease and highlights its potential to provide clinically meaningful...

Continue reading

AleAnna, Inc. Announces Completion of Several Major Milestones for its Renewable Natural Gas (RNG) Business

The company has completed the acquisition of three biogas plants in Italy AleAnna, Inc. has begun generating revenue from plants in Tuscany and Piedmont The Italian Government has granted capital incentives for construction of AleAnna’s Campagnatico plant projectDALLAS and ROME, Dec. 18, 2024 (GLOBE NEWSWIRE) — AleAnna, Inc., (“AleAnna” or the “Company”) (Nasdaq: ANNA), today announced the completion of a series of initiatives through which the Company has expanded or proven out aspects of its renewable natural gas business. These include the purchase of majority working interests in three Italian biogas plants, first corporate revenue generation from its plant operations, and demonstration of the Company’s ability to secure Italian Government capital incentives for the construction of biogas plants and their conversion to biomethane...

Continue reading

First Helium Provides Year End Corporate Update

Company Outlines Plans for 2025 CALGARY, Alberta, Dec. 18, 2024 (GLOBE NEWSWIRE) — First Helium Inc. (“First Helium” or the “Company”) (TSXV: HELI) (OTCQB: FHELF) (FRA: 2MC) today provided a Corporate Update regarding its plans for 2025 via a message from President & CEO, Ed Bereznicki. “As we move into 2025, I’m excited to share our plans at this pivotal moment for First Helium. With two high-impact drilling targets identified and funded for near-term execution, our comprehensive technical work through 2024 has set the stage for what promises to be a transformational year ahead. With our recent financing complete, raising $3.64 million with significant participation from management, we are funded to execute on two near-term, high-impact oil opportunities in Q1 2025, subject to any unforeseen weather conditions and services...

Continue reading

Cielo Provides Update on Rocky Mountain Clean Fuels Transaction

Rocky Mountain Clean Fuels Secures $20 Million Provincial Grant to be Assigned to Cielo CALGARY, Alberta, Dec. 18, 2024 (GLOBE NEWSWIRE) — Cielo Waste Solutions Corp. (TSXV:CMC; OTC PINK:CWSFF) (“Cielo” or the “Company”), a company fueling renewable change, is pleased to provide an update on its proposed acquisition of an Enhanced Gas to Liquids (“EGTL™”) facility located in Carseland, Alberta (the “EGTL Facility”), currently owned and operated by Rocky Mountain Clean Fuels Inc. (“RMCFI”), which deploys patented Enhanced Gas-To-Liquids technology (the “EGTL™ Technology”) designed to make synthetic diesel and jet fuel from natural gas and natural gas liquids, which was developed by Expander Energy Inc. (“Expander”). Cielo holds an exclusive licence in Canada from Expander for a patented Enhanced Biomass to Liquids...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.